Adenosine N1-oxide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562513

CAS#: 146-92-9

Description: Adenosine N1-oxide is an inhibitor of secretion of inflammatory mediators. It acts by suppressing pro-inflammatory cytokine secretion.

Chemical Structure

img
Adenosine N1-oxide
CAS# 146-92-9
Instruction

Theoretical Analysis

MedKoo Cat#: 562513
Name: Adenosine N1-oxide
CAS#: 146-92-9
Chemical Formula: C10H13N5O5
Exact Mass: 283.09
Molecular Weight: 283.240
Elemental Analysis: C, 42.41; H, 4.63; N, 24.73; O, 28.24

Price and Availability

Size Price Availability Quantity
50mg USD 500
Bulk inquiry

Synonym: Adenosine N1-oxide; Adenosine N1 oxide; Adenosine N1oxide; ANO; Adenosine, 1-oxide;

IUPAC/Chemical Name: (2R,3R,4S,5R)-2-(1-Hydroxy-6-iminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

InChi Key: QHFLZHVITNUFMV-KQYNXXCUSA-N

InChi Code: InChI=1S/C10H13N5O5/c11-8-5-9(13-3-15(8)19)14(2-12-5)10-7(18)6(17)4(1-16)20-10/h2-4,6-7,10-11,16-19H,1H2/t4-,6-,7-,10-/m1/s1

SMILES Code: O[C@H]1[C@H](N2C=NC3=C2N=CN(O)C3=N)O[C@H](CO)[C@H]1O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 283.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Harvey R, McCaughan C, Wise LM, Mercer AA, Fleming SB. Orf virus inhibits interferon stimulated gene expression and modulates the JAK/STAT signalling pathway. Virus Res. 2015 Oct 2;208:180-8. doi: 10.1016/j.virusres.2015.06.014. Epub 2015 Jun 22. PubMed PMID: 26113305.

2: Kohno K, Ohashi E, Sano O, Kusano H, Kunikata T, Arai N, Hanaya T, Kawata T, Nishimoto T, Fukuda S. Anti-inflammatory effects of adenosine N1-oxide. J Inflamm (Lond). 2015 Jan 20;12(1):2. doi: 10.1186/s12950-014-0045-0. eCollection 2015. PubMed PMID: 25632271; PubMed Central PMCID: PMC4308844.

3: Deng L, Dai P, Ding W, Granstein RD, Shuman S. Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells. J Virol. 2006 Oct;80(20):9977-87. PubMed PMID: 17005676; PubMed Central PMCID: PMC1617288.

4: Smee DF, Sidwell RW. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52. Review. PubMed PMID: 12615302.

5: Baker RO, Bray M, Huggins JW. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003 Jan;57(1-2):13-23. PubMed PMID: 12615299.

6: Najarro P, Traktman P, Lewis JA. Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation. J Virol. 2001 Apr;75(7):3185-96. PubMed PMID: 11238845; PubMed Central PMCID: PMC114112.

7: Hilton JC, Temple CA, Rajagopalan KV. Re-design of Rhodobacter sphaeroides dimethyl sulfoxide reductase. Enhancement of adenosine N1-oxide reductase activity. J Biol Chem. 1999 Mar 26;274(13):8428-36. PubMed PMID: 10085074.

8: Signorini N, Molko D, Cadet J. Polyclonal antibodies to adenine N1-oxide: characterization and use for the measurement of DNA damage. Chem Res Toxicol. 1998 Oct;11(10):1169-75. PubMed PMID: 9778313.

9: Kwong CD, Krauth CA, Shortnacy-Fowler AT, Arnett G, Hollingshead MG, Shannon WM, Montgomery JA, Secrist JA 3rd. Synthesis and antiviral evaluation of analogs of adenosine-N1-oxide and 1-(Benzyloxy)adenosine. Nucleosides Nucleotides. 1998 Aug;17(8):1409-43. PubMed PMID: 9672703.

10: Kane EM, Shuman S. Adenosine N1-oxide inhibits vaccinia virus replication by blocking translation of viral early mRNAs. J Virol. 1995 Oct;69(10):6352-8. PubMed PMID: 7666536; PubMed Central PMCID: PMC189534.

11: Szabados E, Hindmarsh EJ, Phillips L, Duggleby RG, Christopherson RI. 5-Aminoimidazole-4-carboxamide ribotide transformylase-IMP cyclohydrolase from human CCRF-CEM leukemia cells: purification, pH dependence, and inhibitors. Biochemistry. 1994 Nov 29;33(47):14237-45. PubMed PMID: 7947835.

12: Shimizu S, Shiozaki S, Ohshiro T, Yamada H. Occurrence of S-adenosylhomocysteine hydrolase in prokaryote cells. Characterization of the enzyme from Alcaligenes faecalis and role of the enzyme in the activated methyl cycle. Eur J Biochem. 1984 Jun 1;141(2):385-92. PubMed PMID: 6428887.

13: Guranowski A, Montgomery JA, Cantoni GL, Chiang PK. Adenosine analogues as substrates and inhibitors of S-adenosylhomocysteine hydrolase. Biochemistry. 1981 Jan 6;20(1):110-5. PubMed PMID: 7470463.

14: Guranowski A, Schneider Z. Purification and characterization of adenosine nucleosidase from barley leaves. Biochim Biophys Acta. 1977 May 12;482(1):145-58. PubMed PMID: 861230.

15: Jebeleanu G, Ty NG, Mantsch HH, Bârzu O, Niac G, Abrudan I. Participation of N1-oxide derivatives of adenine nucleotides in the phosphotransferase activity of liver mitochondria. Proc Natl Acad Sci U S A. 1974 Nov;71(11):4630-4. PubMed PMID: 4373722; PubMed Central PMCID: PMC433942.

16: Frederiksen S, Jorgensen AO, Rasmussen AH, Tonnesen T. The effect of adenosine N1-oxide on the incorporation of radioactive precursors into the nucleic acids. Mol Pharmacol. 1968 Jul;4(4):358-66. PubMed PMID: 5690986.

17: Sigel H, Brintzinger H. [Inosine-N(1)-oxide nucleotide in complex formation. I. Synthesis of inosine-N(1)-oxide and its 5'-monophosphate from adenosine-N(1)-oxide and its 5'monophosphate by deamination with nitrosyl chloride]. Helv Chim Acta. 1965 Apr 20;48(3):433-7. German. PubMed PMID: 5863920.

18: KOESSEL H, DOEHRING S. REACTION OF ADENOSINE-1-N-OXIDE WITH DIAZOTIZED SULFANILIC ACID. Biochim Biophys Acta. 1965 Apr 19;95:663-4. PubMed PMID: 14324817.